Calidi Biotherapeutics
CLDI
42 hedge funds and large institutions have $204M invested in Calidi Biotherapeutics in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 3 closing their positions.
67% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 3
57% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 7
5% more funds holding
Funds holding: 40 → 42 (+2)
1% more capital invested
Capital invested by funds: $202M → $204M (+$1.6M)
0.01% more ownership
Funds ownership: 0.74% → 0.75% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
+$7.44M |
| 2 |
Millennium Management
New York
|
+$5.47M |
| 3 |
PAMP
Polar Asset Management Partners
Toronto,
Ontario, Canada
|
+$2.88M |
| 4 |
SC
Sculptor Capital
New York
|
+$2.63M |
| 5 |
Parallax Volatility Advisers
San Francisco,
California
|
+$2.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
-$11.5M |
| 2 |
AMH
Apollo Management Holdings
New York
|
-$7.42M |
| 3 |
HCM
Highbridge Capital Management
New York
|
-$4.31M |
| 4 |
PCM
Pinz Capital Management
New York
|
-$564K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$275K |
CLDI Hedge Fund Activity: Q2 2022 in Review
42 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Calidi Biotherapeutics (CLDI) for Q2 2022, worth a combined $204M — up 0.79% from $202M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CLDI positions and 3 closed out — a net gain of 2 holders — while 11 added to existing stakes and 7 trimmed.
The largest buyer was Nomura Holdings, adding an estimated $7.44M. The largest seller was Beryl Capital Management, exiting entirely with an estimated $11.5M sold.
- 42 institutional investors held Calidi Biotherapeutics (CLDI) as of Q2 2022, up from 40 in Q1 2022.
- Funds reported $204M of Calidi Biotherapeutics stock for Q2 2022, up 0.79% quarter-over-quarter.
- 5 funds opened new Calidi Biotherapeutics positions in Q2 2022 and 3 closed out, a net change of +2 holders.
- The largest Calidi Biotherapeutics buyer in Q2 2022 was Nomura Holdings, an estimated $7.44M added.
- The largest Calidi Biotherapeutics seller in Q2 2022 was Beryl Capital Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q2 2022.